目的:探讨降脂药辛伐他汀对肾病综合征高脂血症患儿的血清脂联素和瘦素及受体水平的影响及其疗效。方法:将肾病综合征患儿55例随机分为治疗组和对照组,另选择同期健康体检儿童20例为健康组。对照组给予泼尼松治疗,治疗组在泼尼松治疗的基础上加用辛伐他汀。于治疗前和治疗4周后分别检测两组患者的血脂指标,并采用ELISA检测脂联素和瘦素及受体含量,计算游离Leptin指数(Leptin/sOBR,FLI)。结果:治疗4周后,两组血脂指标均下降,但是研究组下降程度明显高于对照组(P<0.01)。治疗前研究组与对照组患儿血清ADPN含量明显高于健康儿童(P<0.05),治疗4周后,研究组患儿血清ADPN含量较治疗前明显下降,而对照组患儿治疗后血清ADPN含量变化不大。治疗前和治疗4周后研究组与对照组患儿血清Leptin含量与健康儿童比较,差异均无统计学意义(P>0.05),变化不明显。治疗前研究组与对照组患儿血清sOBR含量明显低于健康儿童(P<0.05),治疗4周后,研究组和对照组患儿血清sOBR含量均较治疗前明显升高,而研究组患儿治疗后血清sOBR含量明显高于对照组(P<0.05)。治疗前研究组与对照组患儿血清FLI明显高于健康儿童(P<0.05),治疗4周后,研究组和对照组患儿血清FLI含量均较治疗前明显下降,而研究组患儿治疗后血清FLI含量明显低于对照组(P<0.05)。结论:辛伐他汀对PNS患儿高脂血症治疗有明显疗效,并能降低患儿血清脂联素和游离瘦素水平。 Objective: To investigate the effect of simvastatin, a lipid-lowering drug, on serum adiponectin and leptin and its receptor in children with nephrotic syndrome and its therapeutic effect. Methods: Fifty-five children with nephrotic syndrome were randomly divided into treatment group and control group. Another 20 healthy children were selected as healthy group. The control group was given prednisone, and the treatment group was given simvastatin on the basis of prednisone treatment. Serum lipids were measured before treatment and after 4 weeks of treatment. Serum levels of adiponectin, leptin and receptor were detected by ELISA. Leptin index (Leptin / sOBF, FLI) was calculated. Results: After 4 weeks of treatment, the levels of serum lipids decreased in both groups, but the decrease in the study group was significantly higher than that in the control group (P <0.01). The levels of ADPN in serum of study group and control group before treatment were significantly higher than those of healthy children (P <0.05). After 4 weeks of treatment, the serum ADPN level in study group decreased significantly compared with that before treatment, while the serum ADPN Little change in content. Before treatment and after 4 weeks of treatment, serum Leptin levels in study group and control group were not significantly different from those in healthy children (P> 0.05). Before treatment, the content of sOBR in study group and control group was significantly lower than that in healthy children (P <0.05). After 4 weeks of treatment, serum sOBR levels in study group and control group were significantly higher than those before treatment, while study group Serum sOBR levels in children after treatment were significantly higher than those in the control group (P <0.05). Before treatment, the serum levels of FLI in study group and control group were significantly higher than those in healthy children (P <0.05). After 4 weeks of treatment, the levels of serum FLI in study group and control group were significantly lower than those before treatment, while those in study group After the serum FLI content was significantly lower than the control group (P <0.05). Conclusion: Simvastatin has a significant effect on the treatment of hyperlipidemia in children with PNS, and can reduce the level of serum adiponectin and free leptin in children.